

## Correction

# Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Xenofon Baraliakos<sup>1</sup>, Joachim Listing<sup>2</sup>, Jan Brandt<sup>1</sup>, Angela Zink<sup>2</sup>, Rieke Alten<sup>3</sup>, Gerd Burmester<sup>4</sup>, Erika Gromnica-Ihle<sup>5</sup>, Herbert Kellner<sup>6</sup>, Matthias Schneider<sup>7</sup>, Helmut Sörensen<sup>8</sup>, Henning Zeidler<sup>9</sup>, Martin Rudwaleit<sup>10</sup>, Joachim Sieper<sup>10</sup> and Juergen Braun<sup>1</sup>

<sup>1</sup> Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany

<sup>2</sup> German Rheumatism Research Center, Berlin, Germany

<sup>3</sup> Schlosspark Clinic, Berlin, Germany

<sup>4</sup> Charité, University Medicine Berlin, Campus Mitte, Germany

<sup>5</sup> Berlin-Buch Hospital, Berlin, Germany

<sup>6</sup> Ludwig-Maximilians-University, Munich, Germany

<sup>7</sup> Heinrich-Heine-University, Düsseldorf, Germany

<sup>8</sup> Private Praxis, Berlin, Germany

<sup>9</sup> Medical University of Hannover, Hanover, Germany

<sup>10</sup> Charité, Medical University of Berlin, Campus Benjamin Franklin, Department of Rheumatology, Germany

Corresponding author: Juergen Braun, [j.braun@rheumazentrum-ruhrgebiet.de](mailto:j.braun@rheumazentrum-ruhrgebiet.de)

Published: 23 March 2005

This article is online at <http://arthritis-research.com/content/7/3/113>

© 2005 BioMed Central Ltd

*Arthritis Research & Therapy* 2005, **7**:113 (DOI 10.1186/ar1750)

After publication of this work [1], we noted that we inadvertently failed to include the complete list of all co-authors. The full list of authors has now been added and the Authors' contributions and Competing interests section modified accordingly.

## Competing interests

Dr Braun and Dr Sieper have held consultancies and received research honoraria, speaker's honoraria and grants/research support from Centocor, Schering-Plough, Essex Pharma, Wyeth and Abbott. Dr Zeidler has received speaker's honoraria from Essex Pharma. Dr Burmester has held consultancies for Centocor, Essex Pharma, Wyeth and Abbott; has received honoraria from Centocor, Essex Pharma, Wyeth and Abbott; has been a member of a speaker's bureau for Centocor, Essex Pharma, Wyeth and Abbott; and has received grants/research support from Centocor, Essex Pharma and Abbott. The other authors declare no conflicts of interest.

## Authors' contributions

XB: Preparation of data analysis, preparation of the manuscript and study coordination; JL, AZ: Data analysis and statistical evaluation; JB, MR: Monitoring and investigation of the patients and study coordination; RA, GB, EG-I, HK, MS, HS, HZ: clinical investigation; JS: Investigator, writing of the manuscript; JB: Idea, writing of the manuscript, principal investigator and responsible for the study.

## References

1. Baraliakos, X, Listing, J, Brandt, J, Rudwaleit, M, Sieper, Braun, J: **Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis (AS) after 3 years of continuous treatment with Infliximab.** *Arthritis Res Ther* 2005, **7**: R439-R444.